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 RESUMO 
Estresse oxidativo causado por hemólise intravascular compõe a fisiopatologia das 
complicações renais na Anemia Falciforme (AF). Mutações que afetam genes 
envolvidos nas vias oxidativa e de sinalização podem estar associadas à doença renal 
nesta importante e frequente condição. Nós determinamos  as frequências alélicas e 
genotípicas de alguns polimorfismos comuns encontrados nas regiões promotoras 
dos genes da Heme Oxigenase 1 (HMOX1) [SNP rs2071746 (A>T) e repetições 
(GT)n, alelos curtos e longos] e do Receptor de Proteína Morfogenética  Óssea - tipo 
1B (BMPR1B) [SNPs rs17022863 (A>G), rs4331783 (A>G) e rs1470409 (A>G)]  em 
75 pacientes AF adultos, em estado estável da doença e sem tratamento com 
hidroxiureia, e as comparamos àquelas encontradas em 160 controles saudáveis 
(doadores de sangue)  provenientes da mesma região geográfica do país e com as 
mesmas características étnicas dos pacientes. Nós também investigamos se esses 
polimorfismos poderiam influenciar a taxa de filtração glomerular estimada (eTFG) 
para esses pacientes. Os quatro SNPs foram genotipados usando ensaios TaqMan, 
enquanto as repetições de HMOX1 (GT)n foram determinadas por análise de 
tamanho de fragmento de PCR. A eTFG foi calculada pela fórmula de Modificação da 
Dieta na Doença Renal (MDDR). Todas as frequências genotípicas aqui determinadas 
encontravam-se em equilíbrio de Hardy-Weinberg. Em relação ao HMOX1 
rs2071746, verificamos que a mediana da eTFG foi significativamente maior nos 
pacientes com o genótipo TT (p=0,019), inclusive quando comparada àquela 
resultante da soma dos valores de eTFG dos pacientes com os genótipos AT e AA 
(p=0,009); em relação às repetições (GT)n, as medianas da eTFG dos três genótipos 
(SS, SL e LL) diferiram significativamente (p= 0,009), e quando LL foi comparado com 
LS + SS, a mediana de LL foi significativamente maior (p=0,005). Estes resultados 
sugerem que tanto o estado homozigótico TT do polimorfismo rs2071746, como os 
homozigotos LL das repetições (GT)n apresentam um risco maior de desenvolver 
complicações renais. Em relação ao gene BMPR1B, as frequências  de homozigotos 
GG do polimorfismo rs17022863 e de homozigotos AA da mutação rs4331783 foram 
significativamente maiores nos pacientes do que nos controles saudáveis (p=0,002 e 
p=0,008,respectivamente), sugerindo que esses genótipos possam estar sob vigência 
de algum tipo de seleção, positiva ou negativa, na doença AF. No entanto, não foram 
detectadas associações significativas entre esses SNPs e os valores de eTFG no 
 grupo de pacientes aqui analisados. De nosso conhecimento, este é o primeiro estudo 
que investiga a associação entre polimorfismos nos genes HMOX1 e BMPR1B e 
eTFG em pacientes brasileiros com AF. Nossos resultados provêem suporte adicional 
para o papel desses genes na nefropatia da AF e podem contribuir para melhores 
prevenção e  acompanhamento desses pacientes. 
 
Palavras-Chave:  Anemia falciforme, Hemólise, Estresse oxidativo, Polimorfismos 
Genéticos, Taxa de filtração glomerular. 
 
 
  
 ABSTRACT 
Oxidative stress caused by hemolysis is implicated in the pathophysiology of renal 
complications in sickle cell anemia (SCA). Mutations affecting genes involved in the 
oxidative and signalling pathways may be associated with kidney disease in SCA. We 
determined the allelic and genotypic frequencies of some common polymorphisms in 
the promoter regions of the Heme Oxygenase 1 (HMOX1) [SNP rs2071746 (A>T) and 
(GT)n repeats, short and long alleles] and Bone Morphogenetic Protein Receptor type 
1 B (BMPR1B) [SNPs rs17022863 (A>G), rs4331783 (A>G) and rs1470409 (A>G)] 
genes in 75 SCA adult patients in a steady state and without hydroxyurea treatment, 
and compared them with those of 160 healthy controls from the same geographical 
region of the country and with the same ethnic characteristics as the patients. We also 
investigated whether these polymorphisms may influence the glomerular filtration rate 
estimated (eGFR) for these patients. The four SNPs were genotyped using TaqMan 
assays, while the HMOX1 (GT)n repeats were determined by PCR fragment size 
analysis. The eGFR was calculated by Modification of Diet in Renal Disease (MDRD) 
formula. All the genotype frequencies were in Hardy-Weinberg equilibrium. Regarding 
HMOX1 rs2071746, we found that the eGFR median was significantly higher in 
patients with the TT genotype (p=0.019), inclusive when TT was compared with 
AT+AA (p=0.009); in relation to the (GT)n repeats, the eGFR medians of the three 
genotypes (SS, SL and LL) significantly  differed (p=0.009), and when LL was 
compared with LS+SS, the LL eGFR median was significantly higher (p=0.005). These 
results suggest that both the homozygous TT for rs2071746 and the homozygous LL 
for (GT)n repeats lead to a higher risk of developing renal complications. Concerning 
BMPR1B, the genotype frequencies of GG for rs17022863 and AA for rs4331783 were 
significantly higher in patients than in controls (p=0.002 and p=0.008, respectively), 
suggesting that these genotypes may be negatively or positively selected in SCA. 
However, we could not find any significant association between these SNPs and the 
eGFR in the group of patients studied here. To our knowledge, this is the first study 
investigating association between polymorphisms in the HMOX1 and BMPR1B genes 
and eGFR in Brazilian SCA patients. Our results provide additional support for the role 
of these genes in SCA nephropathy and may contribute to prevention and better 
follow-up of these patients. 
 Keywords: Sickle Cell Anemia, Hemolysis, Oxidative stress, Genetic Polymorphisms, 
Glomerular Filtration Rate. 
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1. INTRODUCTION 
 
1.1 Sickle Cell Anemia 
 
    Sickle cell anemia (SCA) is a homozygous inheritance of abnormal sickle hemoglobin 
(HbS), a single β globin gene mutation (GAG>GTG) at the sixth codon of the human β 
globin gene (HBBS), on chromosome 11 specifically on the short arm position 15.5. This 
mutation occur as a result of substitution of glutamic acid for valine residue (glu6val) 
(HBB:c.20A>T; p.E7V) leading to polymerization of HbS molecules. During 
deoxygenation the HbS molecule polymerizes and this causes the erythrocytes to 
assume a sickle shape, the sickle cell becomes stiff and inflexible to pass through small 
capillaries [1,2]. SCA is characterized by chronic vaso-occlusion and severe hemolytic 
anemia associated with endothelial dysfunction. SCA is known to be clinically 
heterozygous despite the fact that all the affected patients are homozygous for gene βS, 
with a wide range of clinical manifestations, including renal complications, acute chest 
syndrome, and leg ulceration [3,4]. 
The highest prevalence of HbS is found in Sub-Saharan African, and parts of the 
Mediterranean region, which include the Middle East and the Indian Subcontinent, 
although the βS gene has spread around the world through population migration [5]. Sub-
Saharan African record the highest percentage of 75% annual new births with SCA [6], and 
the demographic projections support the fact that this high prevalence is likely to grow 
further in coming decades [5-7]. It is generally believed that HbS was imported to Brazil 
mainly by slave trade during the colonial period and as a result of population migration 
[6,8,9]. In Brazil, the prevalence of the βS allele ranges from 1.2% to 10%, depending on 
the region of the country [6]. The prevalence of HbS in Brazil in 2010 was 1 per 650, 1 per 
1,200 and 1 per 4,000 live births in Bahia, Rio de Janeiro and Sao Paulo respectively [6]. 
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1.2 Pathophysiology of Sickle Cell Anemia 
SCA is characterized by a complex pathophysiology that leads to deformation of red 
blood cells (RBC) which affect the physical properties of RBC [10]. In SCA HbS 
polymerization is the essential pathophysiological occurrence which is highly dependent 
on the oxygen tension. The replacement of glutamic acid, a polar amino acid, by valine, a 
nonpolar amino acid at 6th codon of the human beta globin gene on chromosome 11p 15.5, 
results in a marked decrease in the solubility of sickle hemoglobin in the deoxygenated 
state, leading to hemoglobin polymerization, tactoid formation, RBC rigidity and 
subsequent RBC membrane damage [10,11]. Change in shape of RBCs is initially 
reversible upon re-oxygenation; however, membrane damage occurs with each episode of 
sickling and eventually influx of calcium, with efflux of potassium and water. Hence the 
RBC eventually becomes irreversible sickle shape, the irreversible sickle RBC becomes 
stiffer with increased amount of HbS polymer and hemolysis is associated with irreversible 
structural changes of sickle RBCs [12]. The Gardos channel is a K+ efflux channel activated 
by the intracellular Ca++ increase due to deoxygenation. Thus, K+ output results in water 
efflux, cell dehydration and increased internal HbS concentration [13]. This leads to cellular 
dehydration, hemolysis and nitric oxide (NO) depletion [14]. Patients are therefore 
susceptible to vaso-occlusion and subsequent organ damage [15]. In addition to episodic 
cycles of ischemia reperfusion injury and subsequent organ damage, abnormal adhesion 
of leukocytes and platelets, coagulation, inflammation and hypoxia are some of the 
characteristics features of SCA. These manifestations are brought about through two major 
pathways: vaso-occlussion with ischemia-reperfusion injury and hemolytic anemia [16], as 
shown in Figure 1. 
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Figure 1:  The alteration in the β globin chain leads to the replacement of glutamic acid for 
valine, resulting in the polymerization of hemoglobin (Hb) molecule when deoxygenated. 
The sickle polymer injuries the erythrocytes and eventually produces irreversible 
membrane damage (Steinberg et al. 2008). 
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1.3  Hemolysis in Sickle Cell Anemia 
   Hemolysis is a common pathophysiologic process in SCA. Erythrocytes injury leads 
to extra and intravascular hemolysis, endothelial dysfunction, vasculopathy, and occlusion 
of small and large blood vessels, in extra-vascular hemolysis where red cells are damaged 
by macrophages in the spleen, liver, bone marrow and reticulo-endothelial system [17], 
while intravascular hemolysis is a potential cause of oxidative injury and endothelial 
damage in SCA, both hemolysis produces tissue ischemia/reperfusion injury and 
inflammation. Sickle erythrocyte has high tendency to hemolyse due to it unstable nature 
of HbS. This therefore, shorten the lifespan of sickle erythrocyte [17]. When Hb is released 
from RBC due to hemolysis, the free Hb and arginase are liberated from  the RBC which 
set in motion a cascade of molecular events that damage vascular endothelium, the 
arginase which destroys arginine leading to nitric oxide (NO) depletion and vascular 
dysfunction and may trigger oxidative tissue damage [17,18].Oxidation of ferrous  to Ferric 
Hb (Fe3+), which generates hydroxyl and lipid peroxyl radicals, promotes vascular and renal 
injury, which may result  to  pulmonary hypertension and chronic kidney disease as patients 
age[19]. Oxidation of hemoglobin can result in the release of free heme into plasma which 
in excess triggers inflammation, vaso-occlusion and coagulation, free heme is removed by 
hemopexin [17]. 
   Free heme released from oxidized Hb induces vascular inflammation and is a major 
source of oxidative stress among patients with SCA, where continuous auto-oxidation of 
extracellular Hb produces superoxide which dismutates into hydrogen peroxide [17]. Thus, 
the level of oxidative stress is higher in SCA patients when compared with healthy 
individuals [20], and free hemoglobin is found to be increased by 10 fold in SCA [21], with 
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an average concentrations of 3.5uM (range 0.4-10.9uM) at steady state and 5.3uM (1.0-
25.3uM) during severe hemolysis [22-23].  
 
1.4   Renal Pathophysiology/Hyperfiltration in SCA 
  SCA associated nephropathy is a growing matter of concern, because renal failure 
affects 12% to 21% of adult SCA patients [24,25] and up to 80% of aging SCA patients 
[26]. Studies have shown that approximately 16-18% of overall mortality in SCA patients 
are associated with kidney disease [27,28]. SCA patients exhibit episodes of hematuria 
and tubular abnormalities as a consequential effect of hemolysis and some of the early 
clinical manifestations [19,26,28], including hyperfiltration, hypertrophy, and impaired 
urinary concentrating ability are described as early as in infancy in SCA patients [28]. 
These are associated with increased renal plasma flow, also result to an increased 
glomerular filtration rate (GFR) [29]. Renal complication in SCA is characterized by 
alterations in renal hemodynamics. Higher GFR is mediated by increased generation of 
nitric oxide as well as an increased production of renal kallikrein and other vasoactive kinins 
[30]. In a study using animal model, it was observed that some nephrons were hypertrophic 
and associated with increased glomerular blood flow, and the afferent arteriolar resistance 
decreases more than the efferent arteriolar resistance which then progresses to kidney 
disease [31].  Consequently, intraglomerular hypertension occurs. Glomerular 
hypertension has been shown in some experimental studies to mediate progressive kidney 
damage following a variety of initiating injuries [31]. Hemolysis is a risk factor for 
hyperfiltration and proteinuria associated with increased GFR among patients with SCA 
[28,32,33]. 
Therefore, mutations in genes involved in oxidative and signalling pathways may 
influence renal function in SCA patients. 
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1.5 HMOX1 Gene 
This gene located on the chromosome 22q12.3 is important gene because of its 
involvement in the oxidative pathway and its protein induced by heme during hemolysis.  
There are two isoforms of Heme oxygenase enzyme (HMOX): the heme oxygenase -1 
(HMOX1) is the inducible isoform while heme oxygenase 2 (HMOX2) is the constitutive 
isoform [34]. The inducible isoform, heme oxygenase-1 (HMOX1), is expressed in various 
tissues, including liver, spleen, lung, and brain and is up-regulated by stimuli, such as 
heme, oxidants hypoxia, oxidative stress and certain cytokines [34]. Oxidative stress 
particularly, appears to be a major factor in HMOX1 induction under pathologic conditions 
[35,36]. It plays a role in the regulation of reactive oxygen species (ROS) mediated 
pathway. HMOX1 catalyses the conversion of heme to biliverdin, carbon monoxide (CO) 
and iron (Fe), biliverdin reductase then converts biliverdin to bilirubin as shown in the 
Figure 2. Both biliverdin and bilirubin have been known to act as scavengers of ROS, and 
carbon monoxide has anti-inflammatory and anti-oxidant effects [37]. HMOX1 is thus 
known as an oxidative stress responsive protein that is usually stimulated by multiple 
stimuli and has been proposed to provide an important cellular response that protects cells 
against oxidative damage. The importance of HMOX1 gene was reported using (Hmox1-1-
) deficient mice which confirmed that this gene is indispensable to survival and in particular, 
to protect  the mice from oxidative stress [38,39]. Another important study revealing the 
importance of this gene was carried out by Shiraishi et al. (2000) with a Hmox1 knock out 
mice (Hmox1-1-) [40], where Hmox1 deficient mice was found with renal injury, severe 
irreversible renal failure and 100% death. This expresses the importance of this gene to 
oxidative injury and its association with marked cytoprotection. In a similar experiment, 
Nath et al.,( 2000) observed the  contrary effect in (Hmox1+1+) mice that displayed mild, 
reversible renal injury, and 0% death [41]. Molecular genetics of the HMOX1 gene provided 
additional support for the protection of the kidney against oxidative stress [42]. Modulated 
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by several identified functional polymorphisms in this gene, humans differ quantitatively in 
their ability to mount HMOX1 response. Investigations into some of the beneficial effects 
of HMOX1 bye products such as CO revealed that this molecule exerts vasodilatory effects 
through cyclic guanosine monophosphate (cGMP) dependent smooth muscle relaxation 
similar to the well-established vasodilator nitric oxide (NO), CO binds to the heme moiety 
of soluble guanylyl cyclase (sGC), causing activation of cGMP and resultant vascular 
relaxation [43]. A number of studies have examined DNA polymorphisms in the HMOX1 
gene that might influence the level of heme oxygenase response [44,19]. 
 There are two most studied promoter variants [a -413A>T(rs2071746) single-
nucleotide polymorphism (SNP) and (GT)n micro satellite polymorphism] several studies 
have reported their functional roles in regulation of heme oxygenase levels [45,46]. When 
stimulated by hydrogen peroxide in vitro, short repeats alleles (<25 repeats depending on 
the cut of the study) show increased promoter activity compared with longer repeats 
alleles (> 25 repeats) [47]. The HMOX1 (GT)n tandem repeats polymorphism has been 
previously shown to correlate with HMOX1 activity [46].  The (GT)n repeats is highly 
polymorphic and accumulating evidence has suggested that persons with lower numbers 
of repeats might have higher inducible heme oxygenase expression [48,49].   
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Figure 2:  Role of heme oxygenase-1 and the actions of its products in response to 
oxidative stress in SCA. Heme oxygenase-1 degrade free heme to biliverdin, iron and 
carbon monoxide (Abraham and Kappas, 2008) 
 
   1.6  BMPR1B Gene 
BMPR1B gene located on chromosome 4q22.3 encodes a member of the bone 
morphogenetic protein (BMP) receptor family and a member of transforming growth factor 
beta (TGFB) superfamily which are large group of structurally related cell regulatory 
proteins [50]. BMP/TGFB initiate signalling across the plasma membrane into the cell by 
inducing heteromeric complexes of type l and type ll receptors with serine/threonine 
kinase activity [51]. Studies have shown that BMP/TGFB signalling molecules regulate 
cell proliferation, differentiation, apoptosis and adhesion of many different cell types 
[50.52,53].Patel et al. (2005) observed that SNPs in the BMPR1B gene were associated 
with nephropathy in Type 1 diabetes [54]. Other studies have also revealed that diabetic 
nephropathy patients share some common features with sickle cell nephropathy, such as 
glomerular hyperfiltration, mesangial cell proliferation and mesangial expansion [54,55]. 
Nolan et al.(2007) studying SCA patients, found that the SNP rs17022863, and the 
combination of SNPs rs17022863, rs4331783 and rs1470409 in haplotypes, are 
significantly associated with the estimated GFR (eGFR) [55].  
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Considering the high prevalence rates of mortality in SCA (16-18%) as a result of 
kidney disease (27,28), genetic variation studies play a vital role in gaining a full 
understanding of renal complications. Hence, SNPs and (GT)n repeats of HMOX1 and 
SNPs of BMPR1B are believed to be involved in oxidative/signalling pathways which may 
influence renal function in SCA. However, there are few studies on mutations in HMOX1 
and BMPR1B and their association with eGFR and, to our knowledge, none in Brazilian 
Sickle Cell Patients. 
Therefore, some mutations in these genes (HMOX1 and BMPR1B) which may 
influence renal function in SCA and the full knowledge about the influence of these 
genetic variants is still not clear. In order to investigate if common polymorphisms in 
HMOX1 and BMPR1B genes might modulate renal function in SCA patients, we 
determined the allelic and genotypic frequencies of rs2071746 and (GT)n repeats in 
HMOX1 and rs17022863, rs4331783, rs1470409 in BMPR1B  in SCA patients and 
controls. We also investigated the association between these mutations and eGFR in the 
group of patients. 
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  2. OBJECTIVES 
 
   General: 
 To investigate the association of common SNPs and (GT)n repeats in HMOX1 and 
BMPR1B genes with estimated glomerular filtration rate (eGFR) in Brazilian 
patients with SCA.  
   Specific:  
 To determine the allelic and genotypic frequencies of rs2071746 and (GT)n repeats 
of HMOX1 and rs17022863, rs1470409, rs4331783 of BMPR1B in SCA patients 
and healthy controls (HbAA).  
 To investigate their influence on the eGFR of these patients. 
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     3. MATERIALS AND METHODS 
                                                                      
     3.1 Study participants 
The study comprised 75 SCA patients (HbSS, 28.3±8.2 years old, 54.7% males) on 
follow up at the Hematology Center of Pernambuco (HEMOPE), in Recife, state of 
Pernambuco, northeast of Brazil. The control group was composed of 160 healthy adults 
(blood donors) (Hb AA, 40±10.1 years old, 78% males) from the same Brazilian region 
and with ethnic characteristics similar to those of the patients. Further information on the 
biodata was obtained by interview and from patient’s medical records. The local ethics 
committee approved this study, and informed consent was obtained from all participants, 
according to the Helsinki Declaration. 
     3.2 SNP Genotyping 
The identification of the HMOX1 -413A>T (rs2071746) and BMPR1 SNPs 
(rs1702283, rs14070409, rs4331783) were performed by TaqMan® SNP genotyping 
assay according to the manufacturers protocol. The SNP genotyping assays used for 
the experiments were presented in the Table 1 (Applied Biosystems, Foster city, CA, 
USA). The final reaction volume was optimized to 5ul reaction containing final reaction 
concentration of both the working stock assay and TaqMan Universal PCR master mix 
75ng of template DNA was added to each reaction. The reactions were performed in 96 
well. TaqMan real time PCR was performed and two no DNA template control (NTCs). 
Initial denaturation step of 95oC  for 10minutes, which was succeeded by 50 cycles 
denaturation, each containing sub steps of fragment denaturation, primer annealing and 
primer extension at 95oC for 15seconds,60oC  for 29seconds and 60oC for 1minute 
respectively.  After PCR amplification, fluorescence signals were analysed on a Step 
One Plus Real Time PCR System (Applied Biosystems, Foster city, CA, USA). 
Genotypes were determined by manually reviewing each allelic discrimination plot with 
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sequence Detection system version 2.3 software (Applied Biosystems, Foster city, CA, 
USA). 
 
 Table1:  SNP genotyping assays used for experiments 
Gene SNPs Context Sequence [VIC/FAM] 
HMOX1 rs2071746 AGTTCCTGATGTTGCCCACCAGGCT[A/T] 
TTGCTCTGAGCAGCAGCGCTGCCTCCCA 
BMPR1B rs1470409 CAGACTCTGTGACTTGGCCTCCTGT[A/G]TAAATCTCGTCC
CAGTACTTTGCA 
 rs4331783 ATTCTGCCACAAACATTCATTCA[A/G]TAGAACATGGCACA
TAGTCCTGGAG 
 rs17022863 GCATTTTAGTCACTGGATTATTACCTGG[A/G]TTTTTAAGTA
TTTTGCATCCCTGTG 
 
 
 
3.3 (GT)n Repeats Genotyping 
The rs3074372 identification was performed by PCR using a forward primer 5'- (6-
FAM) labelled (*) for detection by fragment analysis in capillary electrophoresis system. 
The PCR reaction was prepared in 30 μL volume with 150ng of genomic DNA, 1X Reaction 
Buffer (BIOTOOLS B&M Labs, Valle de Tobalina, Madrid, Spain), 2.16mM MgCl2, 1.33 mM 
of dNTP mix, 133 nM of each primer [named HMOX1_prom_*F 
(AGAGCCTGCAGCTTCTCAGA) and HMOX1_prom_R 
(ACAAAGTCTGGCCATAGGAC)] (21) and 1 U Taq DNA Polymerase (BIOTOOLS B&M 
Labs Valle de Tobalina, Madrid, Spain). Thermal cycle conditions were as follows:  
preheating at 96°C by 2 minutes, followed by 25 cycles of 96°C for 30 seconds, 60°C for 
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40 seconds, and 72°C for 40 seconds. An ended step at 72°C for 30 min was performed 
to promote adenylation of the PCR products. The PCR product (1 μL) was added to 8.7 μL 
Hi-Di Formamide (Applied Biosystems, Carlsbad, CA, USA) and 0.3 μL of a GeneScan™ 
500 LIZ™ size standard (Applied Biosystems, Carlsbad, CA, USA) and  the fragments 
ranged from 92 - 160 bp, corresponding to 12 - 46 fragment repeats, respectively, were 
separated by capillary electrophoresis on a ABI 3500 Genetic Analyzer, analysed by Gene 
Mapper  v4.1 Software (both Applied Biosystems, Carlsbad, CA, USA) and classified  
according to Bean et al.( 2012) as short (S), with ≤ 25 repeats, and long (L), with ˃ 25 
repeats [56]. 
3.4 The estimated Glomerular Filtration Rate (eGFR) 
The serum creatinine levels and the eGFR of these SCA patients were previously 
obtained [57]. Estimated Glomerular Filtration Rates were determined by Modification of 
Diet in Renal Disease (MDRD): 
eGFR(mL/min/1.73m2)= 175 x (SCR mg/dL)-1.154 x (Age) -0.203 x (0.742) if female (58). 
 
3.5 Statistical Analysis 
 
Statistical analyses were performed using Statistical Analysis System (SAS) version 
9.4 (SAS Institute Inc. Cary, USA). Data were reported as Means, Percentages and 
Standard deviations. Gender and Age were adjusted using logistic regression. Hardy-
Weinberg Equilibrium (HWE) was checked by chi square test. Mann-Whitney test was 
used to compare two variables. One-way ANOVA was used to compare three variables. 
The p<0.05 value were considered statistical significance. 
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ABSTRACT 
Oxidative stress caused by hemolysis is implicated in the pathophysiology of renal 
complications in sickle cell anemia (SCA). Mutations affecting genes involved in the 
oxidative and signalling pathways may be associated with kidney disease in SCA. We 
determined the allelic and genotypic frequencies of some common polymorphisms in 
the promoter regions of the Heme Oxygenase 1 (HMOX1) [SNP rs2071746 (A>T) and 
(GT)n repeats, short and long alleles] and Bone Morphogenetic Protein Receptor type 
1 B (BMPR1B) [SNPs rs17022863 (A>G), rs4331783 (A>G) and rs1470409 (A>G)] 
genes in 75 SCA adult patients in a steady state and without hydroxyurea treatment, 
and compared them with those of 160 healthy controls from the same geographical 
region of the country and with the same ethnic characteristics as the patients. We also 
investigated whether these polymorphisms may influence the glomerular filtration rate 
estimated (eGFR) for these patients. The four SNPs were genotyped using TaqMan 
assays, while the HMOX1 (GT)n repeats were determined by PCR fragment size 
analysis. The eGFR was calculated by Modification of Diet in Renal Disease (MDRD) 
formula. All the genotype frequencies were in Hardy-Weinberg equilibrium. Regarding 
HMOX1 rs2071746, we found that the eGFR median was significantly higher in patients 
with the TT genotype (p=0.019), inclusive when TT was compared with AT+AA 
(p=0.009); in relation to the (GT)n repeats, the eGFR medians of the three genotypes 
(SS, SL and LL) significantly  differed (p=0.009), and when LL was compared with 
LS+SS, the LL eGFR median was significantly higher (p=0.005). These results suggest 
that both the homozygous TT for rs2071746 and the homozygous LL for (GT)n repeats 
lead to a higher risk of developing renal complications. Concerning BMPR1B, the 
genotype frequencies of GG for rs17022863 and AA for rs4331783 were significantly 
higher in patients than in controls (p=0.002 and p=0.008, respectively), suggesting that 
these genotypes may be negatively or positively selected in SCA. However, we could 
not find any significant association between these SNPs and the eGFR in the group of 
patients studied here. To our knowledge, this is the first study investigating association 
between polymorphisms in the HMOX1 and BMPR1B genes and eGFR in Brazilian SCA 
patients. Our results provide additional support for the role of these genes in SCA 
nephropathy and may contribute to prevention and better follow-up of these patients. 
 
     Keywords: Sickle Cell Anemia, Hemolysis, Oxidative stress, Genetic Polymorphisms, 
Glomerular Filtration Rate. 
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INTRODUCTION 
Sickle cell anemia (SCA) is a chronic and severe hemolytic anemia associated with 
endothelial dysfunction, vaso-occlusion and inflammation. It is caused by a homozygous 
inheritance of a single point mutation (GAG>GTG) at the 6th codon of the β globin gene, 
on 11p15.5, resulting in the replacement of glutamic acid for valine at the 6th position of 
the β  globin chain and leading to the formation of hemoglobin S (HbS) (HBB:c.20A>T; 
p.E7V). Deoxy-HbS polymerizes inside the erythrocytes resulting in the formation of 
sickled red blood cells, related to the hemolysis and vaso-occlusive events, organ 
damage and a wide range of clinical manifestations [1-4].   
One of the most important clinical complications in SCA is kidney disease, 
responsible for 15-18% of the mortality rate in adult patients [3,4]. In the early stages, it 
includes glomerular hyperfiltration, glomerular enlargement, and hematuria [5-7], 
progressing to chronic kidney disease (CKD) [8]. Hemolysis seems to be related to the 
pathogenesis of renal disease in SCA [9-11]. Chronic hemolysis results in high renal 
plasma flow which can lead to endothelial dysfunction causing hemodynamic changes 
that result to renal functional and structural abnormalities and, consequently, increase 
in glomerular filtration rate (GFR) [6,7,11]. Genetic variants of genes related to oxidative 
and signalling pathways, as the Heme Oxygenase-1 (HMOX1) and Bone Morphogenetic 
Protein Receptor Type 1B (BMPR1B) genes, respectively, have been associated with 
some of the clinical complications in SCA, such as stroke, osteonecrosis and acute 
chest pain [12-15]. Studies have revealed that in these patients the release of free heme 
triggers the formation of reactive oxygen species (ROS) and oxidative stress, induces 
HMOX1 activity and increases the conversion of oxidized angiotensinogen to 
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angiotensin II, which mediates the generation of signalling molecules, capable of 
inducing systemic responses leading to renal damage [16-18].  
HMOX1 is the rate limiting enzyme that degrades heme through oxidation to yield 
equimolar quantities of biliverdin, carbon monoxide (CO) and free iron (Fe) [19]. A 
severe, irreversible renal failure with 100% death was found in mice deficient Hmox1 (-
/-) in contrast with Hmox1 (+/+) mice, that showed mild, reversible renal injury and 0% 
mortality [20]. HMOX1 gene has two promoter variants that have been widely studied, 
a -413 A>T single nucleotide polymorphism (SNP) (rs2071746) and a (GT)n 
microsatellite polymorphism [21]. Short repeats (n≤25 or n<27, according to the cut off 
of different studies) have been associated with higher gene expression levels than the 
long (GT)n repeats (n≥25 or n≥27) [21].  
BMPR1B gene encodes a member of the bone morphogenetic protein (BMP) 
receptor family of transmembrane serine/threonine kinases. The ligands of this receptor 
are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in 
endochondral bone formation and embryogenesis. These proteins transduce their 
signals through the formation of heteromeric complexes of two different types of serine 
(threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of 
about 70-80 kD [22]. Patel et al. observed that some SNPs in the BMPR1B gene are 
associated with nephropathy in Type 1 diabetes [23]; Nolan et al., studying SCA 
patients, found that the SNP rs17022863, and the combination of SNPs rs17022863, 
rs4331783 and rs1470409 in haplotypes, are significantly associated with the estimated 
GFR (eGFR) [24]. 
In Brazil the prevalence of the βs allele is high, varying from 1.2% to 10.9% depending 
on the region of the country [4]. To our knowledge, there are no studies evaluating the 
influence of polymorphisms in the HMOX1 and BMPR1B genes on the renal function in 
Brazilian SCA patients. Thus, the aim of this study was to determine and compare the 
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allelic and genotypic frequencies of the SNP rs2071746 and (GT)n repeats in the 
HMOX1 gene and the SNPs rs17022863, rs4331783 and rs1470409 in the BMPR1B 
gene between Brazilian adult SCA patients and healthy controls and investigate whether 
these polymorphisms may influence the eGFR of these patients.  
 
MATERIALS AND METHODS 
The study comprised 75 SCA patients (HbSS, 28.3±8.2 years old, 54.7% males) on 
follow up at the Hematology and Hemotherapy Center of Pernambuco (HEMOPE), in 
Recife, state of Pernambuco, northeast of Brazil. The patients were in a steady state and 
without hydroxyurea treatment for at least three months. The control group was 
composed of160 healthy adults (blood donors) (Hb AA, 40±10.1 years old, 78% males) 
from the same Brazilian region, with ethnic characteristics similar to those of the patients.  
Further information on the biodata was obtained by interview and from patient’s medical 
records. The local ethics committee approved this study, and informed consent was 
obtained from all participants, according to the Helsinki Declaration. 
Genomic DNA from all patients and controls was extracted from peripheral blood (25). 
The SNPs were genotyped by TaqMan® SNP Genotyping Assay in the Step One Plus 
Real-Time PCR system according to the manufacturer protocol (Applied Biosystems, 
Foster city, CA, USA). The (GT)n repeats were identified by capillary electrophoresis on 
a ABI3500 Genetic Analyzer, using the Gene Mapper  v 4.1 Software (both Applied 
Biosystems, Carlsbad, CA, USA).  They were classified according to Bean et al., 2012 
as short (S) with ≤ 25 repeats and long (L) with ˃ 25 repeats [15]. 
The eGFR was determined in the SCA patients by using the simplified prediction 
equation MDRD (Modification Diet in Renal Disease): eGFR (mL/min/1.73m2) = 175 x 
(serum creatinine mg/dL)- 1.154 x (age)- 0.203 x 0.742 (if female) (9).   
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Statistical Analysis System (SAS) for Windows version 9.4 (SAS Institute Inc, Cary, 
U.S.A) was used for the analysis. Allelic and genotypic frequencies were determined in 
both, patients and controls.  Hardy-Weinberg Equilibrium (HWE) was checked by X2 
test.  Age and gender were adjusted using regression logistics. One way ANOVA was 
used to compare three variables, while Mann-Whitney was used to compare two 
variables against eGFR in SCA patients. The p values <0.05 were considered 
statistically significant. 
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RESULTS 
 The allelic and genotypic frequencies found for rs2071746 are presented in Table 
1,(Appendix ; Figure 1) while those found for the (GT)n repeats in the HMOX1 gene are 
shown in Table 2 (Appendix; Figure 2). 
Table 1.  Allelic and genotypic frequencies for rs2071746 in the HMOX1 gene 
         
 
 
 
 
 
 
 
 
 
 
HWE: Hardy-Weinberg equilibrium, n: number, SNP: Single Nucleotide Polymorphism, eGFR; estimated Glomerular Filtration 
Rate 
  
SNPs Alleles/ 
Genotypes 
SCA Patients 
n=74 
Controls 
n=131 
p-
values 
 
Median eGFR 
(mL/min/1.73m2) 
p-values 
eGFR 
 
 
HMOX1 
rs2071746 
A 48.0% 55.0%    
T 52.0% 45.0%  
AA 18 (24.3%) 37 (28.2%)  
0.39 
156.22  
0.019 AT 33 (48.6%) 69 (52.7%) 161.46 
TT 20 (27.0%) 25 (19.1%) 188.39 
 TT  
AT+AA 
20 (27%) 
54 (73%)           
25 (19.1%) 
106 
(80.9%) 
 188.39 
160.86 
 
0.009 
HWE p-
value 
 0.82 0.47    
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Table 2: Distribution of genotype frequencies of the (GT)n repeats in the HMOX1 gene 
Genotypes SCA patients 
n=75 
Controls  
n=160 
p-values Median eGFR 
(mL/min/1.73m2) 
p-values 
eGFR 
LL 42 (56.0%) 85 (53.1%)  
0.92 
173.83  
0.009 SL 28 (37.3%) 64 (40.0%) 143.20 
SS 5 (6.7%) 11 (6.9%) 193.94 
SL+LL 70 (93.3%) 149 (93.1%)  
0.95 
163.63  
0.74 SS 5 (6.7%) 11 (6.9%) 193.94 
  LL 42 (56.0%) 85 (53.1%)  
0.68 
173.83  
0.005 SL+SS 33 (44.0%) 75 (46.9%) 147.52 
HWE p-value 0.91 0.82    
HWE: Hardy-Weinberg equilibrium, n: number, L: Long, S: Short, eGFR: estimated glomerular filtration rate 
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The allelic and genotypic frequencies for rs17022863, rs4331783 and rs1470409 in the BMPR1B 
gene in SCA patients and controls are presented in Table 3 ( Appendix ;Figure 3). 
Table 3:  Allelic and Genotypic frequencies for rs17022863, rs4331783 and rs1470409 in the 
BMPR1B gene 
SNPs Allele/ 
Genotypes 
SCA 
Patients 
 n=75 
Controls 
n=132 
p-
values 
Median eGFR 
(mL/min/1.73m2) 
p-
values 
eGFR 
 
 
BMPR1B 
rs17022863 
A 59.0% 72.0%    
G 41.0% 28.0%  
AA 27 (36.0%) 66 (50.8%)  
0.002 
166.61  
0.87 AG 35 (46.7%) 56 (43.1%) 161.62 
GG 13 (17.3%) 8 (6.2%) 192.94 
p-value 
(HWE) 
 0.77 0.38    
 
 
BMPR1B   
rs1470409 
A 44.0% 45.0%    
G 56.0% 55.0%  
AA 13 (17.3%) 27 (21.3%)  
0.16 
180.06  
0.94 AG 40 (53.3%) 63 (49.6%) 161.38 
GG 22 (29.3%) 37 (29.1%) 168.90 
p-value 
(HWE) 
 0.47 0.98    
 
 
A 44.0% 69.0%    
G 56.0% 31.0%  
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HWE: Hardy-Weinberg equilibrium, n: number, SNP: Single Nucleotide Polymorphism, eGFR: estimated Glomerular Filtration 
Rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMPR1B 
rs4331783 
AA 13 (18.0%) 8 (6.1%)  
 
0.008 
185.36  
0.83 AG 37 (51.4%) 65 (49.2%) 161.29 
GG 22 (30.5%) 59 (44.7%) 166.13 
p-value 
(HWE) 
 0.71 0.070    
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Discussion 
HMOX1 enzymes have been known for its anti-oxidant and anti-inflammatory activities 
[26-28]. In SCA, these enzymes are particularly important to protect patients from the 
damaging effects of excess heme released by high rates of chronic intravascular 
hemolysis [28]. A recent study with SCA mice has shown that induction of HMOX1 protein 
significantly inhibits inflammatory markers and vaso-occlusion [29]. We determined the 
allelic and genotypic frequencies of two common polymorphisms in the promoter region 
of the HMOX1 gene in Brazilian adult SCA patients and compared them with those found 
in a control group. The frequencies were all in HWE. We also investigated whether the 
different genotypes related to these two polymorphisms could influence the eGFR of our 
patients. Regarding rs2071746, we observed that the eGFR median was significantly 
higher in patients with the TT genotype (p=0.019), inclusive when TT was compared with 
AT+AA (p=0.009). This finding is in agreement with previous studies which found 
association of the T allele with reduction of HMOX1 gene expression [15,30] and suggests 
that patients with the TT genotype are at higher risk of developing renal complications. In 
relation to the (GT)n repeats, the eGFR medians of the three genotypes (SS, SL and LL) 
significantly  differed (p=0.009); when LL was compared with LS+SS, the LL eGFR 
median was significantly higher  (p=0.005). This result also suggests that patients with 
the LL genotype may have higher risk of renal disease  progression, supporting the 
concept that long alleles are associated with decreased HMOX1 activity, as found by 
Chen et al in patients with coronary artery disease [31].  
The BMPR1B gene plays an important role in cell proliferation, inflammatory response 
and tissue repair.  In our patients and controls, the allelic and genotypic frequencies of the 
SNPs rs17022863, rs4331783 and rs14070409 were all in HWE; statistical differences 
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between them were found for two SNPs, rs17022863 and rs4331783 (p=0.002 and 0.008, 
respectively), suggesting that they are being negatively or positively selected in SCA. 
However, we could not find any significant association of the different genotypes with 
eGFR, in contrast to Nolan findings, as previously commented [24]. Okocha et al. (2010) 
[32], investigating other polymorphisms in the same gene, and Saraf et al. (2015) [18], 
analysing four polymorphisms, three of which we analysed, also we could not observe 
association among the different genotypes and eGFR in SCA patients. The differences 
commonly observed in different studies may be due to different composition of the 
populations and/or sample sizes [33,34].  
To our knowledge, this is the first study determining the allelic and genotypic frequencies 
of common polymorphisms in the HMOX1 and BMPR1B genes and investigating their 
association with eGFR in Brazilian SCA patients. Our results showed that the homozygous 
TT for rs2071746 and homozygous LL for (GT)n repeats in the promoter region of HMOX1 
were associated with significantly higher eGFR medians, providing additional support for 
the role of HMOX1 in renal complications in SCA patients. These results may contribute to 
prevention measures and better follow-up of our patients and, with other studies, allow a 
better understanding of the genetic factors related to the development of renal 
complications in SCA. We could not find any association among the SNPs rs17022863, 
rs4331783 and rs14070409 in the promoter region of the BMPR1B genes and eGFR in the 
group of patients studied here. 
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      5. DISCUSSION 
Intravascular hemolysis is a potential cause of oxidative injury and endothelial 
dysfunction in SCA [33]. Human proximal tubular cell exposed to free hemoglobin has 
increased tendency of kidney injury, reduced viability and induction of HMOX1 due to 
hemolysis [33,34]. HMOX1 enzyme, is induced in response to oxidative stress function as 
cytoprotective protein in SCA patients from cytotoxic effect of heme, which are released by 
chronic intravascular hemolysis [59]. Studies revealed that SNPs in HMOX1 are associated 
with various disease conditions including renal complications [56,60].Therefore SNPs found 
in HMOX1 gene may modulate renal function in SCA patients. In this study we determined 
the allelic and genotypic frequencies of SNPs in the promoter region of HMOX1 gene in 
Brazilian adult SCA patients and compared them with that of the control group. We also 
investigated if the different genotypes of these SNPs could influence the eGFR of the 
patients. The genotypic frequencies were in the Hardly-Weinberg equilibrium (HWE) and no 
difference between the patients and the controls. On HMOX1 rs2071746 we did not observe 
a significant differences in the genotype frequencies when comparing patients and controls 
(p=0.38). The medians of the three genotypes AA, AT and TT showed significant difference 
among SCA patients (p=0.019).  Regarding the association of the different genotypes SCA 
patients carrying the homozygous TT genotype had significant higher levels of eGFR when 
compared with other genotypes (p=0.019). In a study it was reported that the T allele in 
HMOX1 rs2071746 was significantly associated with reduced HMOX1 activity [45]. This then 
suggest that these patients are at risk of developing CKD, the possible explanation may be 
the genetic variants decreases the regulation of HMOX1 protein and therefore less protein 
may be available and greater concentration of heme will increase in circulation.   
 The (GT)n repeats, the eGFR medians of the three genotypes (SS,SL and LL) 
significantly differed (p=0.009) when LL was compared with LS + SS, the LL eGFR  median 
44  
was significantly higher (p=0.005). A hypothesis to explain these findings is that the 
homozygous genotype LL may be associated with reduced levels of HMOX1 activity there 
by exposing the patient to high risk of oxidative stress which may progress to CKD, a similar 
observation was made by Chen et al., where they reported the (GT)n long repeats in 
HMOX1 was associated with CKD among patients with coronary artery disease [61]. In a 
similar report made by Saraf et al.(2015) but in a different HMOX1 SNPs rs743811 where 
long (GT)n repeats were associated with CKD in 247 adults African Americans SCA 
patients[60]. Furthermore, Bean et al.(2012) who observed that African American children 
with SCA, with short (GT)n repeats were associated with lower rates of hospitalization for 
acute chest syndrome [56]. 
 All the SNPs studied here in BMPR1 gene (rs17022863, rs4331783 and rs14070409); 
the allelic and genotypic frequencies were in HWE and did not significantly differ between 
patients and controls. Our result of SCA patients did not reveal any association with the 
eGFR, in contrast with the findings by Nolan et al. (2007), who found that SNPs in 
BMPR1B gene were associated with eGFR in SCA patients [55]. The differences 
observed between our study and that of Nolan and colleagues who researched on the 
same SNPs with our candidate SNPs may be due to different composition of the 
population and sample size. However, the distribution of genotype frequencies for 
rs17022863 and rs4331783 were significantly different between SCA patients and healthy 
controls, with (p=0.002) and (p=0.008) respectively. These differences may be as a result 
of natural selection in favour or against one of the two alleles compared, but possibly 
regarding some other clinical manifestation or complication [62,63]. 
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     6. CONCLUSION 
 
To our knowledge, this is the first study investigating association of genetic variants of 
HMOX1/BMPR1B genes with eGFR in adult Brazilian SCA patients. Hence, our results 
revealed that homozygous TT and homozygous LL genotypes in the promoter region of 
SNP HMOX1 rs 2071746 were significantly associated with eGFR in adult Brazilian SCA 
patients, both genotypes are associated with significant higher eGFR medians. Our results 
further reaffirmed the important role played by HMOX1 as an antioxidant in the oxidative 
pathway. Further studies is recommended which would further validate our findings for 
better understanding of renal complication influenced by genetic variants. Early 
identification of high risk SCA patients, can contribute to a better management of SCA 
patients. All three SNPs rs17022863, rs4331783 and rs14070409 in BMPR1 did not show 
any association with eGFR in our SCA patients.  
Limitation of the study: the samples size in our study group were small. 
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Figure 1: Estimation of the glomerular filtration rate (mL/min/1.73m2).Calculated by the 
MDRD Method, in patients with sickle cell anemia according to the rs2071746 
polymorphism of HMOX1. The X axis represents the HMOX1 genotype and the Y axis to 
eGFR (Statistical test used, n=75).The values are represented by means ± standard 
deviation. (A) HMOX1 rs 2071746 (p=0.019) (B) HMOX1 rs 2071746 (p=0.009) 
 
 
A 
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Figure 2: Estimation of the glomerular filtration rate (mL/min/1.73m2). Calculated by the 
MDRD method, in patients with sickle cell anemia according to the BMPR1 the X axis 
represents the BMPR1 genotype and the Y axis to eGFR (Statistical test used, n=75). The 
values are represented by means ± standard deviation: (A) p=0.94 (B) p=0.87 and(C) 
p=0.83 
 
 
 
 
 
 
 
 
 
 
 
53  
 
 
9. Appendix 2 
 Ethical approval 
 
 
 
  
54  
 
 
 
 
 
 
 
55  
 
 
 
 
 
 
56  
 
 
 
 
 
 
 
57  
 
 
 
 
 
 
 
